Form 4: Xeris Biopharma Director Sherman Acquires 50,000 Shares Through Restricted Stock Unit Award

Director Jeffrey W. Sherman acquired 50,000 shares of Xeris Biopharma Holdings, Inc. through a restricted stock unit award, according to a recent SEC Form 4 filing.

Summary

• On June 5, 2024, Jeffrey W. Sherman, a director of Xeris Biopharma Holdings, Inc., acquired 50,000 shares of common stock.
• The acquisition was made through a restricted stock unit (RSU) award under the company's 2018 Stock Option and Incentive Plan.
• The RSUs will vest in full on June 5, 2025, or the date of the company's next annual meeting of stockholders, whichever comes first.
• Following the transaction, Sherman directly owns 164,380 shares of Xeris Biopharma Holdings, Inc.
• Sherman also indirectly owns 5,400 shares through the JEFFREY W SHERMAN LIVING TRUST U/A DTD 03/21/2001.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares by a director suggests confidence, but it's a routine transaction.

Positives

• The acquisition of shares by a director can be seen as a positive sign, indicating confidence in the company's future prospects.

Future Outlook

The vesting of the restricted stock units on June 5, 2025, or at the next annual meeting, represents a future event that will result in the issuance of common stock to the reporting person.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in the pharmaceutical industry as part of executive compensation packages.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it signals confidence from a company director.

Key Dates